Review of recent clinical studies with olanzapine

British Journal of Psychiatry

Volumn 174, Issue FEB. SUPPL. 37, 1999, Pages 30-35

  Tollefson, Gary D ^a   Kuntz, Amy J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE; PROLACTIN; RISPERIDONE;

ANXIETY NEUROSIS; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DELUSION; DEPRESSION; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; HUMAN; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SLEEP DISORDER; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; METABOLISM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DEPRESSIVE DISORDER; DRUG RESISTANCE; HUMANS; PIRENZEPINE; PROLACTIN; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0033050956     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000293641     Document Type: Review

References (22)

1. Andreasen, N. C. (1982) Negative symptoms in schizophrenia. Archives of General Psychiatry, 39, 784-788.
2. Barnes, T. R. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
3. Beasley, C. M., Jr, Sanger, T., Satterlee, W., et al (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159-167.
4. _, Tollefson, G. D.,Tran, P.V., et al (1996b) Olanzapine versus placebo and haloperidol: acute-phase results of the North American double-blind olanzapine trial. Neuropsychopharmocology, 14, 105-118.
5. _, Hamilton, S. H., Crawford, A. M., et al (1997a) Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. European Neuropsychopharmocohgy, 7, 125-137.
6. _, Tollefson, G. D. & Tran, P.V. (1997b) Efficacy of olanzapine: an overview of pivotal clinical studies. Journal of Clinical Psychiatry, 58 (suppl. 10), 7-12.
7. Crawford, A. M. K., Beasley, C. M., Jr & Tollefson, G. D. (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 26, 41-54.
8. Dellva, M. A.,Tran, P., Tollefson, G. D., et al (1997) Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services, 48, 1571-1577.
9. Glazer, W. M. (1997) Olanzapine and the new generation of antipsychotic agents: patterns of use. Journal of Clinical Psychiatry, 58 (suppl. 10), 18-21.
10. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (revised version). Bethesda, MD: US Department of Health, Education and Welfare.
11. Harrow, M., Yonan, C. A., Sands, J. R., et al (1994) Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophrenia Bulletin, 20, 327-338.
12. Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T. (1984) The Quality of Life Scale: an instrument for rating schizophrenia deficit syndrome. Schizophrenia Bulletin, 10, 388-398.
13. Kay, S. R., Opler, L. A. & Fiszbein, A. (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems Inc.
14. Nemeroff, C. B. (1997) Dosing the antipsyc hotic medication olanzapine. Journal of Clinical Psychiatry, 58 (suppl. 10), 45-49.
15. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 1231 IBZM single photon emission tomography (SPET) study. Psychopharmacology, 124, 148-153.
16. Tollefson, G. D. & Sanger, T. M. (1997) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466-474.
17. _, Beasley, C. M., Jr. Tamura, R. N., et al (1997a) A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248-1254.
18. _, _, Tran, P.V., et al (1997b) Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
19. _, Tran, P.V., Birkett, M., et al (1997c) Treatment failure with clozapine. Can olanzapine be the alternative therapy? Schizophrenia Research, 24, 191.
20. _, Sanger, T. M., Lu, Y., et al (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry, 55, 250-258.
21. Tran, P.V., Hamilton, S. H., Kuntz, A. J., et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407-418.
22. Woerner, M. G., Mannuzza, S. & Kane, J. M. (1988) Anchoring the BPRS: an aid to improved reliability. Psychopharmacology Bulletin, 24, 112-117.